Email Page Print Page

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

2011 Archives

Dec 29, 2011
FDA's approval of class-wide REMS puts ONSOLIS in an improved competitive position
Nov 28, 2011
Decision supports BDSI's position regarding the invalidity of MonoSol's '588 Patent
Nov 10, 2011
Positive data would allow for initiation of pivotal bioequivalence study in January
Nov 7, 2011
BDSI to receive $300,000 milestone payment
Oct 25, 2011
New independent director brings extensive biotech industry and legal experience to BDSI Board
Sep 28, 2011
Primary endpoint in overall population not achieved but significant pain control observed in the opioid "experienced" group of patients (p=0.067)
Sep 6, 2011
Promising data allows for the potential initiation of pivotal bioequivalence study by year-end
Aug 22, 2011
Product Available in Canada This Quarter Through Meda Valeant
Jul 25, 2011
Reporting of top-line efficacy results anticipated in mid to late September
May 5, 2011
Company presents Thursday, May 12 at 3:30 P.M. EDT
Apr 5, 2011
Reporting of top-line efficacy results remains on target for third-quarter 2011
Mar 2, 2011
Definitive bioequivalence study results compared to Suboxone anticipated by year-end